6. Mai 2024 – On 1 May, Novocure Luxembourg a wholly owned subsidiary of NovoCure Limited (NASDAQ: NVCR), a global oncology company, engaged in the development, manufacture, and commercialisation of tumour treating fields (TTFields) devices for the treatment of solid tumour cancers, closed a secured term loan financing for up to USD 400 million from funds managed by Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds.

Walder Wyss team advised the funds managed by Pharmakon Advisors, LP. The team was led by Tervel Stoyanov (Counsel, Banking & Finance).